Iron is essential for multiple bacterial processes and is thus required for host colonization and infection. The antimicrobial activity of multiple iron chelators and gallium-based therapies against different bacterial species has been characterized in preclinical studies. In this review, we provide a synthesis of studies characterizing the antimicrobial activity of the major classes of iron chelators (hydroxamates, aminocarboxylates and hydroxypyridinones) and gallium compounds. Special emphasis is placed on recent in-vitro and in-vivo studies with the novel iron chelator DIBI. Limitations associated with iron chelation and gallium-based therapies are presented, with emphasis on limitations of preclinical models, lack of understanding regarding mechanisms of action, and potential host toxicity. Collectively, these studies demonstrate potential for iron chelators and gallium to be used as antimicrobial agents, particularly in combination with existing antibiotics. Additional studies are needed in order to characterize the activity of these compounds under physiologic conditions and address potential limitations associated with their clinical use as antimicrobial agents.
Allogeneic hematopoietic stem cell recipients (allo-HSCT) are at high risk for morbidity and mortality from influenza respiratory virus infection (RVI). Vaccination is the primary method for preventing influenza RVI. Although the influenza vaccine is able to achieve serological response in some allo-HSCT recipients, its clinical benefit is still uncertain. In this prospective cross-sectional study, we retrospectively analyzed the effect of inactivated trivalent influenza vaccination status on the prevalence of influenza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018). Respiratory virus in upper and/or lower respiratory tract specimens were tested using multiplex PCR panel assays. Overall, we diagnosed 74 episodes (46%) of Influenza RVI in 70 allo-HSCT recipients. Influenza RVI occurred in 51% of the non-vaccinated compared to 36% of the vaccinated recipients (p= 0.036). Multivariate analysis showed that influenza vaccination was associated with lower prevalence of influenza RVI (OR 0.39, p= 0.01). Multivariate risk factor analysis of lower respiratory tract disease (LRTD) identified two conditions associated with the probability of influenza RVI progression; influenza vaccination (OR 0.12, 95% C.I. 0.014–1, p= 0.05) and high-risk immunodeficiency score index (OR 36, 95% C.I. 2.26–575, p= 0.011). Influenza vaccination was also associated with lower likelihood of influenza-related hospital admission (14% vs 2%, p= 0.04). This study shows that influenza vaccination may have a clinical benefit in allo-HSCT recipients with virologicallly confirmed RVI, in terms of lower influenza RVI prevalence, LRTD progression and hospital admission.